Fundamental Analysis of INSTIL BIO INC(NASDAQ:TIL) stock

Fundamental Rating

Overall TIL gets a fundamental rating of 2 out of 10. We evaluated TIL against 568 industry peers in the Biotechnology industry. While TIL seems to be doing ok healthwise, there are quite some concerns on its profitability. TIL does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TIL has reported negative net income.

TIL had a negative operating cash flow in the past year.

In the past 5 years TIL always reported negative net income.

In the past 5 years TIL always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of TIL (-27.58%) is better than 71.68% of its industry peers.

The Return On Equity of TIL (-42.63%) is better than 71.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-27.58%
ROE	-42.63%
ROIC	N/A

ROA(3y)-39.98%

ROA(5y)-40.08%

ROE(3y)-52.91%

ROE(5y)-50.43%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TIL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TIL has less shares outstanding than it did 1 year ago.

TIL has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -2.64, we must say that TIL is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of TIL (-2.64) is comparable to the rest of the industry.

A Debt/Equity ratio of 0.47 indicates that TIL is not too dependend on debt financing.

TIL has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: TIL underperforms 73.27% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.47
Debt/FCF	N/A
Altman-Z	-2.64

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.90 indicates that TIL has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 12.90, TIL belongs to the top of the industry, outperforming 86.37% of the companies in the same industry.

TIL has a Quick Ratio of 12.90. This indicates that TIL is financially healthy and has no problem in meeting its short term obligations.

TIL has a better Quick ratio (12.90) than 86.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.9
Quick Ratio	12.9

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.87%, which is quite impressive.

EPS 1Y (TTM)56.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%65.96%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TIL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.38% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y47.4%

EPS Next 2Y16.65%

EPS Next 3Y25.38%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TIL. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TIL's earnings are expected to grow with 25.38% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.65%

EPS Next 3Y25.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TIL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INSTIL BIO INC

NASDAQ:TIL (12/20/2024, 8:00:01 PM)

After market: 20.61 0 (0%)

20.61

+0.53 (+2.64%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2024-11-13/bmo

Earnings (Next)N/A N/A

Inst Owners70.89%

Inst Owner Change21.86%

Ins Owners5%

Ins Owner Change0%

Market Cap134.58M

Analysts77.5

Price Target102.34 (396.56%)

Short Float %4.59%

Short Ratio1.75

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-21.2%

Min EPS beat(2)-66.31%

Max EPS beat(2)23.92%

EPS beat(4)2

Avg EPS beat(4)-19.43%

Min EPS beat(4)-66.31%

Max EPS beat(4)30.75%

EPS beat(8)4

Avg EPS beat(8)-77%

EPS beat(12)5

Avg EPS beat(12)-54.17%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-3.22%

PT rev (3m)342.65%

EPS NQ rev (1m)-9.78%

EPS NQ rev (3m)-9.78%

EPS NY rev (1m)-24.19%

EPS NY rev (3m)-24.64%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)33.32%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.76
P/tB	0.76
EV/EBITDA	N/A

EPS(TTM)-11.56

EYN/A

EPS(NY)-15.34

Fwd EYN/A

FCF(TTM)-10.5

FCFYN/A

OCF(TTM)-8.96

OCFYN/A

SpS0

BVpS27

TBVpS27

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-27.58%
ROE	-42.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-39.98%

ROA(5y)-40.08%

ROE(3y)-52.91%

ROE(5y)-50.43%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.47
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	257.44%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	12.9
Quick Ratio	12.9
Altman-Z	-2.64

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)1316.52%

Cap/Depr(5y)4909.14%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)56.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%65.96%

EPS Next Y47.4%

EPS Next 2Y16.65%

EPS Next 3Y25.38%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y46.8%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year60.91%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y75.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y68.54%

OCF growth 3YN/A

OCF growth 5YN/A

INSTIL BIO INC (TIL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens